“This usability study is a key milestone in advancing NASARIX™ toward clinical trials, which are expected to commence in Q3 2026,” said Tomer Izraeli, CEO of Polyrizon. “It underscores our commitment ...

Polyrizon Ltd. ( (PLRZ) ) has provided an announcement.

A hands-on review of the Gerber Edict that looks at how its larger size and low price point translate into real-world cutting ...

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no ...

Comparisons between the Oppo Find N5 and Samsung’s foldables have sparked strong reactions. This review examines specific ...

Several recent steps move the closure toward commercialization RAVENSBURG, GERMANY, January 15, 2026 /EINPresswire.com/ ...

BlueRidge Life Sciences ("BlueRidge"), a leading life sciences consulting and services platform and a portfolio company of Renovus Capital Partners, today announced the acquisition of Design Science, ...

VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

Skilled nursing facilities (SNFs) with a high volume of referred patients with Alzheimer disease and related dementias may work harder to manage care transitions with less availability of resources ...

Aesyra SA is a Swiss spin-off from EPFL (École Polytechnique Fédérale de Lausanne) focused on developing smart, data-driven ...

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no ...

Background: Consensus Reporting Items for Studies in Primary Care (CRISP) is a research-reporting guideline developed for primary care. Because no ...